BACKGROUND: Orally administered SNX-5422, a novel, selective prodrug of the Heat shock protein 90 (Hsp90) inhibitor SNX-2112, was investigated in two sequential phase I studies to determine the safety, maximum tolerated doses (MTDs) and pharmacokinetic profile of SNX-5422. METHODS: Using a dose-escalation design, 3-6 adults with advanced solid tumours received SNX-5422 every-other-day (QOD) or once-daily (QD) 3weeks on/1week off or QD continuously, with disease assessments every 8 weeks. Single-dose and steady-state pharmacokinetic parameters of SNX-2112 were determined. RESULTS: In total, 56 patients were enrolled: QOD 3 weeks on/1 week off, n=36; QD 3weeks on/1 week off, n=17; QD continuous, n=3. Doses ranged from 4 to 133mg/m(2) QOD and 50 to 89 mg/m(2) QD. The MTDs were defined as 100mg/m(2) QOD and 67 mg/m(2) QD, respectively, with diarrhoea being dose-limiting on both 3 weeks on/1 week off schedules. Overall, treatment-related adverse events were mainly low grade, including diarrhoea (64%), nausea (39%), fatigue (28%), and vomiting (28%). Reversible grade 1-3 nyctalopia (night blindness) was reported by four patients (dose: 50-89mg/m(2) QD; 100mg/m(2) QOD). Exposure was generally linear, though greater than dose-proportional. Of 32 evaluable patients on QOD dosing, there was one durable complete response (prostate cancer), one confirmed (HER2+breast cancer) and one unconfirmed partial response (adrenal gland cancer). Three patients (QOD schedule) had stable disease for ⩾ 6 months. CONCLUSIONS: The dose and schedule recommended for further study with SNX-5422 is 100mg/m(2) QOD 3 weeks on/1 week off based on improved tolerability and preliminary evidence of clinical activity.
BACKGROUND: Orally administered SNX-5422, a novel, selective prodrug of the Heat shock protein 90 (Hsp90) inhibitor SNX-2112, was investigated in two sequential phase I studies to determine the safety, maximum tolerated doses (MTDs) and pharmacokinetic profile of SNX-5422. METHODS: Using a dose-escalation design, 3-6 adults with advanced solid tumours received SNX-5422 every-other-day (QOD) or once-daily (QD) 3weeks on/1week off or QD continuously, with disease assessments every 8 weeks. Single-dose and steady-state pharmacokinetic parameters of SNX-2112 were determined. RESULTS: In total, 56 patients were enrolled: QOD 3 weeks on/1 week off, n=36; QD 3weeks on/1 week off, n=17; QD continuous, n=3. Doses ranged from 4 to 133mg/m(2) QOD and 50 to 89 mg/m(2) QD. The MTDs were defined as 100mg/m(2) QOD and 67 mg/m(2) QD, respectively, with diarrhoea being dose-limiting on both 3 weeks on/1 week off schedules. Overall, treatment-related adverse events were mainly low grade, including diarrhoea (64%), nausea (39%), fatigue (28%), and vomiting (28%). Reversible grade 1-3 nyctalopia (night blindness) was reported by four patients (dose: 50-89mg/m(2) QD; 100mg/m(2) QOD). Exposure was generally linear, though greater than dose-proportional. Of 32 evaluable patients on QOD dosing, there was one durable complete response (prostate cancer), one confirmed (HER2+breast cancer) and one unconfirmed partial response (adrenal gland cancer). Three patients (QOD schedule) had stable disease for ⩾ 6 months. CONCLUSIONS: The dose and schedule recommended for further study with SNX-5422 is 100mg/m(2) QOD 3 weeks on/1 week off based on improved tolerability and preliminary evidence of clinical activity.
Authors: Ranjit K Mehta; Sanjima Pal; Koushik Kondapi; Merna Sitto; Cuyler Dewar; Theresa Devasia; Matthew J Schipper; Dafydd G Thomas; Venkatesha Basrur; Manjunath P Pai; Yoshihiro Morishima; Yoichi Osawa; William B Pratt; Theodore S Lawrence; Mukesh K Nyati Journal: Clin Cancer Res Date: 2020-07-27 Impact factor: 12.531
Authors: Martin Gutierrez; Robin Guo; Giuseppe Giaccone; Stephen V Liu; Zhonglin Hao; Christie Hilton; James M Hinson; Mark G Kris; Everardus Otto Orlemans; Alexander Drilon Journal: Lung Cancer Date: 2021-10-08 Impact factor: 5.705
Authors: Si Hyoung Kim; Jun Goo Kang; Chul Sik Kim; Sung-Hee Ihm; Moon Gi Choi; Hyung Joon Yoo; Seong Jin Lee Journal: Endocrine Date: 2015-07-29 Impact factor: 3.633
Authors: Dora Posfai; Amber L Eubanks; Allison I Keim; Kuan-Yi Lu; Grace Z Wang; Philip F Hughes; Nobutaka Kato; Timothy A Haystead; Emily R Derbyshire Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: María González-Cao; Jordi Rodón; Niki Karachaliou; Jesús Sánchez; Mariacarmela Santarpia; Santiago Viteri; Sara Pilotto; Cristina Teixidó; Aldo Riso; Rafael Rosell Journal: Ann Transl Med Date: 2015-10
Authors: Ankush Kanwar; Benjamin J Eduful; Linda Barbeto; Piero Carletti Bonomo; Andrea Lemus; Brian A Vesely; Tina S Mutka; Ala Azhari; Dennis E Kyle; James W Leahy Journal: ACS Med Chem Lett Date: 2017-07-31 Impact factor: 4.632
Authors: Srikumar M Raja; Swapnil S Desale; Bhopal Mohapatra; Haitao Luan; Kruti Soni; Jinjin Zhang; Matthew A Storck; Dan Feng; Timothy A Bielecki; Vimla Band; Samuel M Cohen; Tatiana K Bronich; Hamid Band Journal: Oncotarget Date: 2016-03-01
Authors: Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh Journal: Oncotarget Date: 2016-07-26